Parvovirus formulation for treating tumors

Patent metadata

Field	Value
Publication number	US-10624935-B2
Application number	US-201715830489-A
Country	US
Kind code	B2
Filing date	Dec 4, 2017
Priority date	Jun 23, 2015
Publication date	Apr 21, 2020
Grant date	Apr 21, 2020

Abstract

Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.

First claim

What is claimed is:

1. A pharmaceutical composition comprising (a) at least 2×10 9 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus selected from the group consisting of LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus and Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl 2 ×2 H 2 O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical acceptable carrier contains 48% Iodixanol (w/v), 0.81 mmol CaCl 2 ×2 H 2 O, 52.80 mmol NaCl, 1.06 mmol KCl, 0.88 mg/ml Tromethamine and 0.07 mg/ml Edetate calcium disodium.

3. The pharmaceutical composition of claim 1 , wherein the parvovirus concentration is between 2×10 9 pfu/ml and 1×10 10 pfu/ml.

4. The pharmaceutical composition of claim 2 , wherein the parvovirus concentration is between 2×10 9 pfu/ml and 1×10 10 pfu/ml.

5. A method for treating a tumor comprising intratumoral or intravenous injection of the pharmaceutical composition of claim 1 .

6. The method according to claim 5 , wherein the tumor is a brain tumor, pancreatic carcinoma, cervical carcinoma, lung cancer, head and neck cancer, breast cancer or colon cancer.

7. A method for treating a tumor comprising intratumoral or intravenous injection of the pharmaceutical composition of claim 2 .

8. The method according to claim 7 , wherein the tumor is a brain tumor, pancreatic carcinoma, cervical carcinoma, lung cancer, head and neck cancer, breast cancer or colon cancer.

9. A method for treating a tumor comprising intratumoral or intravenous injection of the pharmaceutical composition of claim 3 .

10. The method according to claim 9 , wherein the tumor is a brain tumor, pancreatic carcinoma, cervical carcinoma, lung cancer, head and neck cancer, breast cancer or colon cancer.

11. A method for treating a tumor comprising intratumoral or intravenous injection of the pharmaceutical composition of claim 4 .

12. The method according to claim 11 , wherein the tumor is a brain tumor, pancreatic carcinoma, cervical carcinoma, lung cancer, head and neck cancer, breast cancer or colon cancer.

Assignees

• Deutsches Krebsforsch
• Univ Heidelberg Ruprecht Karls

Inventors

• Leuchs Barbara
• Geletneky Karsten
• Rommelaere Jean
• Dinsart Christiane
• Dahm Michael
• Krebs Ottheinz

Classifications

• A61K47/02

  Inorganic compounds · CPC title

• A61K35/768 Primary

  Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766 · CPC title

• A61K47/24

  containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids · CPC title

• A61K9/0085

  Brain, e.g. brain implants; Spinal cord · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title